Gary Guthart

The da Vinci surgical system — with over 9,000 units installed in hospitals worldwide — has become the gold standard for minimally invasive surgery in urology, gynecology, general surgery, hernia repair, and an expanding list of procedures. Intuitive's market share exceeds 80%, creating one of the deepest competitive moats in all of medical technology. Intuitive's business model mirrors the classic razor-and-blade approach: each da Vinci system costs $1-2 million, but the recurring revenue from instruments ($700-3,500 per procedure) and service contracts generates the majority of the company's revenue and profits. With millions of procedures performed annually, this recurring stream provides exceptional earnings visibility. Guthart has also overseen the launch of the Ion bronchoscopic system for lung biopsy and the next-generation da Vinci 5 platform, which incorporates force feedback and enhanced visualization. Guthart's decisions on new system platform development, procedure expansion into new surgical specialties, international market penetration, and the company's response to emerging competitors like Medtronic's Hugo and J&J's Ottava are the primary drivers of Intuitive's stock price. The secular trend toward robotic-assisted surgery — still representing less than 5% of applicable procedures globally — provides decades of growth runway.